R&D | Cutting-edge science and innovative research

News

AZ considers filings for long-acting Strensiq follow-up

AstraZeneca's long-acting Strensiq follow-up efzimfotase alfa has hit the mark in children with rare disease HPP, but the data in adults is unclear.

News

Blackstone closes record $6.3bn life sciences fund

Blackstone has closed its latest fund – the $6.3bn BXLS VI – saying it is the largest ever private fund for the life sciences sector.

News

Obesity-focused biotech Kailera joins IPO queue in US

Kailera Therapeutics has filed for an IPO, hoping to whet investor appetites with its pipeline of drug candidates for weight loss.

R&D

Changing Faces: Board of Directors and Advisory Boards, Febr...

Boardrooms and advisory panels across pharma, biotech, medtech, and digital health were busy last month.

News

Otsuka grows in neuroplastogens with $1.225bn Transcend buy

Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.

R&D

Open science: disrupting scientific community collaboration

The quiet rise of collaboration among pharma companies has never been more important.

News

Concentra gatecrashes Jounce and Redx’ merger party

Biotech interloper is led by Kevin Tang of Tang Capital management, which owns 10% of Jounce.

News

UK Chancellor’s budget welcomed by biopharma sector

Industry groups are happy with news on R&D tax credits, funding for MHRA, and investment zones.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

AZ considers filings for long-acting Strensiq follow-up

AstraZeneca's long-acting Strensiq follow-up efzimfotase alfa has hit the mark in children with rare disease HPP, but the data in adults is unclear.

News

Blackstone closes record $6.3bn life sciences fund

Blackstone has closed its latest fund – the $6.3bn BXLS VI – saying it is the largest ever private fund for the life sciences sector.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

Changing Faces: Board of Directors and Advisory Boards, Febr...

Boardrooms and advisory panels across pharma, biotech, medtech, and digital health were busy last month.

R&D

Ending trial-and-error: How psychedelics and precision medic...

The next phase of psychiatry must go toward treatments that are not only novel, but practical, personalised, and accessible.

R&D

Regulatory setback or scientific signal? The case for human-...

Exploring a systemic challenge in translating biological promise into reliable human efficacy and safety.

Deep Dive

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

Beyond obesity: How GLP-1s are changing the game for hundred...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

pharmaphorum podcast Episode 250, Rob DiCicco, Transcelerate

Making AI work where it matters, with Rob DiCicco

Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.

R&D

pharmaphorum podcast Episode 249, Michelle Werner, Alltrna

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

R&D

pharmaphorum podcast Episode 248, Andrew Mackinnon, Medable

AI in clinical development & ‘white space’, with Andrew Mack...

Andrew Mackinnon, senior vice president and executive general manager at Medable, discusses leveraging AI to transform & accelerate development.

Video

R&D

Interview at BIO-Europe 2026 with Robert Jacks

BIO-Europe Spring 2026: In conversation with Robert Jacks

R&D

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.

R&D

The long-delayed promise of the microbiome, with Sam Possemi...

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

White Papers

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D